carbapenems has been researched along with doripenem in 327 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (doripenem) | Trials (doripenem) | Recent Studies (post-2010) (doripenem) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 404 | 33 | 235 |
| Protein | Taxonomy | carbapenems (IC50) | doripenem (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 1.9953 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.22) | 18.2507 |
| 2000's | 102 (31.19) | 29.6817 |
| 2010's | 211 (64.53) | 24.3611 |
| 2020's | 10 (3.06) | 2.80 |
| Authors | Studies |
|---|---|
| Irie, T; Iso, Y; Motokawa, K; Nishino, Y; Nishitani, Y | 1 |
| Irie, T; Iso, Y; Iwaki, T; Kii, M; Motokawa, K; Nishitani, Y; Sendo, Y | 1 |
| Hikida, M; Mitsuhashi, S; Mori, M; Nasu, T; Nishihara, T | 1 |
| Ishii, Y; Miyazaki, S; Ohno, A; Tsuji, M; Yamaguchi, K | 1 |
| Hayasaki, Y; Hua, YX; Izumi, K; Mikamo, H; Sato, Y; Tamaya, T | 1 |
| Nagayama, A; Nomura, S | 1 |
| Ge, Y; Livermore, DM; Mushtaq, S | 2 |
| Blosser-Middleton, RS; Ge, Y; Karlowsky, JA; Sahm, DF; Wikler, MA | 1 |
| Biedenbach, DJ; Fritsche, TR; Huynh, HK; Jones, RN; Sader, HS | 1 |
| Biedenbach, DJ; Huynh, HK; Jones, RN | 2 |
| Brown, SD; Traczewski, MM | 2 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Lynch, AS | 1 |
| Chen, Y; Garber, E; Ge, Y; Kaniga, K; Saiman, L; Wikler, MA; Zhao, Q | 1 |
| Ambrose, PG; Bhavnani, SM; Cirincione, BB; Hammel, JP; Wikler, MA | 1 |
| Bradley, D | 1 |
| Engel, AE; Glass, D; Li, C; Wexler, HM | 1 |
| Kobayashi, Y | 1 |
| Fritsche, TR; Jones, RN; Stilwell, MG | 1 |
| Inamatsu, K; Saito, A; Shiba, T; Shimada, J; Shuden, S; Yamaguchi, K; Yokoyama, T | 1 |
| Abe, K; Arai, T; Hasebe, N; Horiuchi, M; Kimura, M; Tokumura, M | 1 |
| Fujimoto, S; Ike, Y; Sakyo, S; Tanimoto, K; Tomita, H | 1 |
| Anderson, DL | 1 |
| Rice, LB | 1 |
| Fujimura, T; Miwa, H; Nishikawa, T; Tsuji, M; Yamano, Y; Yutsudou, T | 1 |
| Nicolau, DP; Sutherland, C | 1 |
| Dilay, L; Hoban, DJ; Karlowsky, JA; Noreddin, AM; Rubinstein, E; Thomson, K; Wiebe, R; Zhanel, GG | 1 |
| Katsube, T; Yamano, Y; Yano, Y | 1 |
| Weigelt, JA | 1 |
| Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T; Urakawa, N | 1 |
| Lister, PD | 1 |
| Appelbaum, PC; Credito, KL; Ednie, LM | 1 |
| Fritsche, TR; Janechek, MJ; Jones, RN; Sader, HS | 1 |
| Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
| Nicolau, DP | 1 |
| Bush, K; Davies, TA; Flamm, RK; Shang, W | 2 |
| Joseph, J; Rodvold, KA | 1 |
| Ikawa, K; Ikeda, K; Kameda, K; Morikawa, N; Ohge, H; Sueda, T; Urakawa, N | 1 |
| Giamarellou, H; Kanellakopoulou, K | 1 |
| Chastre, J; Friedland, I; Kaniga, K; Lee, M; Prokocimer, P; Wunderink, R | 1 |
| Gilbert, D | 1 |
| Kobayashi, Y; Sumitani, Y | 1 |
| Giamarellou, H; Poulakou, G | 2 |
| Banevicius, MA; Kim, A; Nicolau, DP | 1 |
| Friedland, I; Gast, C; Ingham, M; Ketter, N; Lee, M; Merchant, S; Nathwani, D; Quintana, A | 1 |
| Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E | 1 |
| Friedland, I; Jasovich, A; Jiang, J; Kaniga, K; Lucasti, C; Umeh, O | 1 |
| Brammer, MK; Chan, P; Gilmor, T; Heatherly, K; Kupiec, TC; Psathas, PA; Schaufelberger, D; Trissel, LA; Trusley, C | 1 |
| Hussar, DA | 1 |
| Cirillo, I; Cuyckens, F; Desai-Krieger, D; Devineni, D; Janssen, C; Kao, LM; Mannens, G; Redman, R; Turner, K; Vaccaro, N; Vermeir, M | 1 |
| Chimura, T; Hirayama, T; Murayama, K; Numazaki, M; Ogawa, H | 1 |
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T | 1 |
| Hedge, DD | 1 |
| Keam, SJ | 1 |
| Brown, NP; Pillar, CM; Sahm, DF; Shah, D; Torres, MK | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Goto, T; Ichiishi, T; Mikamo, H; Nakao, K; Tanaka, K; Watanabe, K; Yamagishi, Y | 1 |
| Alba, V; Marti, S; Sánchez-Céspedes, J; Vila, J | 1 |
| Porath, AD | 1 |
| French, GL | 1 |
| Honda, N; Ikawa, K; Kumon, H; Monden, K; Morikawa, N; Uehara, S; Yamada, Y | 1 |
| Ikeda, K; Kuzmission, A; Psathas, PA; Yasuo, S | 1 |
| Goff, DA; Mangino, JE; Schafer, JJ | 1 |
| Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
| Lancaster, JW; Matthews, SJ | 1 |
| Bell, JM; Mendes, RE; Rhomberg, PR; Sader, HS; Turnidge, JD | 1 |
| Citron, DM; Goldstein, EJ | 1 |
| Castanheira, M; Jones, RN; Livermore, DM | 1 |
| Ambrose, PG; Andes, DR; Bhavnani, SM; Van Wart, SA | 1 |
| Bell, JM; Jones, RN; Sader, HS; Stilwell, MG; Turnidge, JD | 1 |
| Fritsche, TR; Jones, RN; Sader, HS; Stillwell, MG | 1 |
| Livermore, DM | 1 |
| Thamlikitkul, V; Trakulsomboon, S | 1 |
| Cleveland, KO; Gelfand, MS; Mazumder, SA | 1 |
| Esterly, JS; Malczynski, M; Postelnick, M; Qi, C; Scheetz, MH | 1 |
| Bito, T; Fukamachi, S; Nakamura, M; Sawada, Y; Sugita, K; Tokura, Y | 1 |
| Dedhia, HV; McKnight, R | 1 |
| Depestel, DD; Paterson, DL | 1 |
| Cirillo, I; Natarajan, J; Redman, R; Solanki, B; Turner, K; Vaccaro, N | 1 |
| Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R | 1 |
| Mandell, L | 1 |
| Sahm, D | 1 |
| Restrepo, MI | 1 |
| File, TM; Redman, R | 1 |
| Amin, A | 1 |
| Rahal, JJ | 1 |
| Friedland, I; Ketter, N; Redman, R; Rubinstein, E; Zhanel, GG | 1 |
| Kawamura, H; Matsumoto, K; Miyanohara, H; Nishi, J; Orita, M; Shigemi, A; Shimodozono, Y; Takeda, Y; Tokuda, K; Yaji, K; Yamada, K | 1 |
| Anan, N; Fujimura, T; Jinushi, Y; Sugimori, G; Watanabe, T; Yamano, Y; Yoshida, I | 1 |
| Bulik, CC; Crandon, JL; Nicolau, DP | 1 |
| Fisher, AC; Jenkins, SG; Kaniga, K; Nicholson, SC; Peterson, JA | 1 |
| Guery, BP | 1 |
| Bush, K; Flamm, R; Queenan, AM; Shang, W | 1 |
| Akhras, K; Caro, JJ; Kongnakorn, T; Merchant, S; Mwamburi, M; Nathwani, D | 1 |
| Katsube, T; Takano, M; Wajima, T; Yamano, Y; Yano, Y | 1 |
| Bonomo, RA; Karpen, ME; Leonard, DA; Powers, RA; Schneider, KD | 1 |
| Danishuddin, M; Khan, AU; Shakil, S | 1 |
| Cattoir, V; Daurel, C | 1 |
| Goto, K; Hagiwara, S; Hidaka, S; Iwasaka, H; Noguchi, T | 1 |
| Overturf, GD | 1 |
| Akhras, K; DeLong, K; Ingham, M; McGarry, LJ; Merchant, S; Nathwani, D; Pawar, V; Thompson, D; Weinstein, MC | 1 |
| Berthoin, K; Carryn, S; Le Duff, CS; Marchand-Brynaert, J; Tulkens, PM | 1 |
| Hibi, H; Honda, N; Ikawa, K; Ikeda, K; Mitsui, K; Morikawa, N; Nakamura, K; Narushima, M; Yamada, Y | 1 |
| Goossens, H; Ieven, M; Jansens, H; Naesens, R; Vlieghe, E | 1 |
| Bogiel, T; Deptuła, A; Gospodarek, E | 1 |
| Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
| Bied, A; Brown, D; Bush, K; Drusano, GL; Fregeau, C; Kahn, JB; Khashab, M; Kulawy, R; Liu, W; Louie, A; Morrow, B; Nicholson, S; Queenan, AM; Van Scoy, B | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K | 1 |
| Esterly, JS; Malczynski, M; Qi, C; Scheetz, MH | 1 |
| Blanchard, JS; Fan, F; Tremblay, LW | 1 |
| Mariano, N; Rahal, JJ; Urban, C | 1 |
| Lin, R; Nandy, P; Samtani, MN | 1 |
| Flamm, R; Kaniga, K; Nandy, P; Samtani, MN | 1 |
| Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A | 1 |
| Hope, R; Livermore, DM; Pllana, T; Warner, M | 1 |
| Betriu, C; Culebras, E; Gómez, M; López-Fabal, F; Picazo, JJ; Rodríguez-Avial, I | 1 |
| Dubreuil, L; Jean-Pierre, H; Mahieux, S; Marchandin, H; Miara, A; Muller-Serieys, C; Neut, C; Soussy, CJ | 1 |
| Amsler, K; Bush, K; Flamm, R; Foleno, B; Santoro, C | 1 |
| Elborn, JS; Parkins, MD | 1 |
| Cacciarelli, TV; Muder, RR; Shields, RK; Singh, N; Sun, HY | 1 |
| Cielecka-Piontek, J; Jelińska, A | 1 |
| Bulik, CC; Nicolau, DP | 1 |
| Chen, J; Mody, SH; Shorr, AF; Zilberberg, MD | 1 |
| Mazzei, T | 1 |
| Crandon, JL; Keel, RA; Nicolau, DP; Sutherland, CA | 1 |
| Araújo, C; Gonçalves, A; Igrejas, G; Poeta, P; Radhouani, H; Rodrigues, J; Silva, N | 1 |
| Crandon, JL; Nicolau, DP; Sutherland, C | 1 |
| Cantón, R; García, A; Gimeno, C; Gobernado, M | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Cassettari, M; Chongthaleong, A; Christiansen, KJ; Cooper, D; Flamm, R; Garcia, J; Hsu, L; Ip, M; Ker, HB; Kiratisin, P; Mendoza, M; Morrissey, I; Okolo, P; Quintana, A; Redjeki, IS | 1 |
| Ko, KS; Lee, H; Peck, KR; Song, JH | 1 |
| Araki, N; Kamihira, S; Kohno, S; Morinaga, Y; Yamada, K; Yamada, Y; Yanagihara, K | 1 |
| Apisarnthanarak, A; Mundy, LM | 2 |
| Buron, JA; Cerrato, SG; Garau, J; Rello, J; Rodriguez, JA; Rossolini, GM; Zaragoza, R | 1 |
| Armand-Lefevre, L; Drugeon, HB; Gjoklaj, M; Kitzis, MD; Lascols, C; Leclercq, R; Legrand, P; Lemire, A; Mérens, A; Miara, A; Moubareck, C; Muller-Serieys, C; Reverdy, ME; Roussel-Delvallez, M; Soussy, CJ | 1 |
| Chahine, EB; Ferrill, MJ; Poulakos, MN | 1 |
| Aguado, JM | 1 |
| Abbanat, D; Barron, A; Bunting, RA; Fernandez, J; Flamm, RK; Hall, L; Hilliard, JJ; Lynch, AS; Melton, JL; Ward, CK | 1 |
| Wilke, MH | 1 |
| Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA | 1 |
| Gautam, V; Kaur, M; Ray, P; Singhal, L | 1 |
| Balis, D; Cirillo, I; Matzke, GR; Redman, R; Vaccaro, N | 1 |
| Bonomo, RA; Leonard, DA; Ortega, CJ; Powers, RA; Renck, NA; Schneider, KD | 1 |
| Chapman, BA; Hellwig, TR; Onisk, ML | 1 |
| Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA | 1 |
| Michalska, K; Pajchel, G; Tyski, S | 1 |
| Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R | 1 |
| Chiang, T; Colon-Urban, R; Eng, RH; Gomez, E; Huang, DB; Mariano, N; Urban, C | 1 |
| Chen, YH; Hsueh, PR; Huang, YT; Ko, WC; Lai, CC; Liu, WL; Tan, HR | 1 |
| Flamm, RK; Korten, V; Laeuffer, JM; Morrissey, I; Mutters, R; Nordmann, P; Picazo, JJ; Quintana, A; Seak, JC | 1 |
| Apisarnthanarak, A; Apisarnthanarak, P; Kiratisin, P; Mundy, LM | 1 |
| Engler, C; Harris, P; Norton, R | 1 |
| Goessens, WH; Mol, M; Pitout, JD; van der Bij, AK; van Westreenen, M | 1 |
| Archontaki, H; Boutos, N; Charkoftaki, G; Dimaraki, E; Margetis, K; Markantonis, S; Sakas, DE; Skoutelis, A; Valsami, G; Vryonis, E | 1 |
| Hirata, S; Kadowaki, D; Nishi, K; Tanoue, K | 1 |
| Akalın, H; Akova, M; Arman, D; Aygen, B; Başaran, S; Bayramoğlu, G; Dizbay, M; Dokuzoğuz, B; Eraksoy, H; Esener, H; Hasçelik, G; Köksal, I; Korten, V; Oğünç, D; Sınırtaş, M; Söyletir, G; Sümerkan, B; Tünger, A; Ulusoy, S; Yalçın, AN | 1 |
| Cabot, G; Cantón, R; del Campo, R; García-Castillo, M; Juan, C; Mulet, X; Oliver, A; Riera, E | 1 |
| Amsler, K; Davies, TA; Flamm, RK; He, W; Lynch, AS; Marie Queenan, A; Morrow, BJ; Pillar, C; Shang, W | 1 |
| Akers, KS; Beckius, ML; Calvano, T; Hospenthal, DR; Markelz, AE; Mende, K; Murray, CK; Yu, X; Zera, WC | 1 |
| Baek, JY; Kang, CI; Ko, KS; Peck, KR; Song, JH | 1 |
| Bonomo, RA; Endimiani, A; Papp-Wallace, KM; Taracila, MA | 1 |
| Abe, T; Goto, K; Hagiwara, S; Hidaka, S; Nishida, T; Noguchi, T; Ohchi, Y; Shitomi, R; Yamamoto, S; Yasuda, N | 1 |
| Bergen, PJ; Bulitta, JB; Forrest, A; Jacob, J; Li, J; Nation, RL; Paterson, DL; Sidjabat, HE; Tsuji, BT | 1 |
| Balderson, BJ; Patil, NP; Suda, KJ; Yates, ME | 1 |
| Daniels, LM; Heil, EL; Nicolau, DP; Smith, EA; Walko, CM | 1 |
| Anan, N; Ito, A; Nakamura, R; Toba, S; Tsuji, M | 1 |
| Harada, M; Hayamizu, Y; Kurono, Y; Nagano, H; Umakoshi, M; Yoshifuku, K | 1 |
| Burian, B; Donath, O; Reznicek, G; Sauermann, R; Zeitlinger, M | 1 |
| Black, PL; Cirillo, I; Kearns, GL; Redman, R; Vaccaro, N | 1 |
| Acosta, F; Cottagnoud, M; Cottagnoud, P; Egerman, U; Laeuffer, JM; Stucki, A | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH | 2 |
| Hagihara, M; Kuti, JL; Nicolau, DP | 1 |
| Decker-Burgard, S; Laeuffer, J; Morrissey, I; Mutters, R; Seifert, H; Valenza, G | 1 |
| DE Sarro, A; Fera, MT; Zummo, S | 1 |
| Botha, F; Burgmann, H; Donath, O; Illievich, UM; Müller, M; Poeppl, W; Wurm, G; Zeitlinger, M | 1 |
| Cleveland, KO; Gelfand, MS | 1 |
| Clancy, CJ; Jernigan, MG; Nguyen, MH; Press, EG; Shields, RK | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Archontaki, H; Boutos, N; Charkoftaki, G; Dimaraki, E; Dokoumetzidis, A; Margetis, K; Markantonis, S; Nalda-Molina, R; Sakas, D; Skoutelis, A; Valsami, G; Vryonis, E | 1 |
| Chen, CC; Cheng, KC; Chiang, SR; Chiu, YH; Chuang, YC; Ko, WC; Ku, YH; Tang, HJ; Zhang, CC | 1 |
| De Waele, JJ; Lipman, J; Paterson, DL; Roberts, JA; Udy, AA | 1 |
| Adier, C; Couet, W; Goldschmidt, P; Grégoire, N; Lamarche, I; Laroche, L; Marchand, S; Semoun, O | 1 |
| Arakawa, M; Honda, N; Ikawa, K; Ikeda, K; Morikawa, N; Nakamura, K; Nishikawa, G; Yamada, Y; Zennami, K | 1 |
| Ichikawa, M; Kurokawa, M; Nannya, Y; Narukawa, K; Toya, T | 1 |
| Inoue, K; Iwasaki, T; Takaku, K; Yamamoto, T | 1 |
| Bowker, KE; Elliott, H; Macgowan, AP; Noel, AR; Tomaselli, SG | 1 |
| Bergen, PJ; Bulitta, JB; Davis, K; Deris, ZZ; Forrest, A; Jacob, J; Ku, CK; Li, J; Nation, RL; Paterson, DL; Poudyal, A; Soon, RL; Tsuji, BT; Velkov, T; Yu, HH | 1 |
| Dundar, D; Kasap, M; Kolayli, F; Torol, S; Vahaboglu, H | 1 |
| Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Kositpantawong, N; Wongpoowarak, W | 1 |
| Farnum, C; Havlichek, DH; Kalra, A; Kulhanek, G; Kuti, JL; Nicolau, DP; Scharmen, A; Smith, CL; Stein, GE; Tran, M | 1 |
| Ito, K; Kato, H; Shibata, Y; Suzuki, K; Suzuki, T | 1 |
| Kato, K; Nishikawa, T; Sakai, Y; Sugiyama, H; Takahashi, M; Tsuyuguchi, T; Yokosuka, O | 1 |
| Chang, SC; Dong, SX; Wang, JT | 1 |
| Keel, RA; Kiratisin, P; Nicolau, DP | 1 |
| Chastre, J; Cirillo, I; Clavel, M; Kaniga, K; Kimko, H; Kollef, MH; Michiels, B; Redman, R; Restrepo, MI | 1 |
| Colakoğlu, S; Durmaz, S; Ekincioğlu, P; Perçin, D | 1 |
| Barszcz, B; Cielecka-Piontek, J; Lewandowska, K; Paczkowska, M | 1 |
| Adamski, P; Bulanda, M; Drzewiecki, A; Sodo, A; Talaga, K | 1 |
| Crandon, JL; Hagihara, M; Nicolau, DP; Urban, CM | 1 |
| Akiyama, N; Kanamaru, A; Masaoka, T; Nakagawa, Y; Ohyashiki, K; Tamura, K; Tanimoto, M; Urabe, A | 1 |
| Lipman, J; Roberts, JA | 1 |
| Dantier, C; Desarbre, E; Gebhardt, K; Hofer, B; Page, MG; Schmitt-Hoffmann, A | 1 |
| van der Meer, YG; van Zanten, AR | 1 |
| Forrest, A; Ly, NS; Rao, G; Soon, RL; Tsuji, B; Wollenberg, L; Yang, K | 1 |
| Kaniga, K; Lee, M; Redman, R; Rice, DA | 1 |
| Ambe, LA; Casella, LG; Doi, Y; Ernst, RK; O'Hara, JA; Pelletier, MR; Shanks, RM; Townsend, BM | 1 |
| Baziaka, F; Galani, L; Giamarellou, H; Karaiskos, I | 1 |
| Crandon, JL; Hagihara, M; Nicolau, DP; Urban, C | 1 |
| Burgmann, H; Lingscheid, T; Mitteregger, D; Poeppl, W; Tobudic, S | 1 |
| Caio, C; Ceccarelli, G; Falcone, M; Giordano, A; Mezzatesta, ML; Stefani, S; Venditti, M | 1 |
| Bhalodi, AA; Keel, RA; Kuti, JL; Lodise, TP; Nicolau, DP; Quintiliani, R | 1 |
| Ito, A; Nakamura, R; Ohta, M; Toba, S; Tsuji, M | 1 |
| Alba, L; Clock, SA; Kubin, CJ; Saiman, L; Tabibi, S; Whittier, S | 1 |
| Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L | 1 |
| Kemper, AL; Young, DC; Zobell, JT | 1 |
| Chida, K; Harada, M; Inui, N; Matsuo, Y; Nakamura, Y; Suda, T; Wajima, T | 1 |
| Hagihara, M; Housman, ST; Kuti, JL; Nicolau, DP | 1 |
| Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 3 |
| Davies, TA; He, W; Lynch, AS; Queenan, AM | 1 |
| Goff, DA; Nicolau, DP | 1 |
| Guzek, A; Korzeniewski, K; Nitsch-Osuch, A; Prokop, E; Rybicki, Z | 1 |
| Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Shimojima, M; Tada, T | 1 |
| Bonomo, RA; June, CM; Kaitany, KC; Klinger, NV; Leonard, DA; Powers, RA; Ramey, ME | 1 |
| Erdogan-Yildirim, Z; Manafi, M; Sauermann, R; Schwameis, R; Strommer, S; Zeitlinger, MA | 1 |
| Chen, L; Cheng, S; Clancy, CJ; Doi, Y; Farrell, AN; Hao, B; Hong, JH; Kreiswirth, BN; Nguyen, MH; Perlin, DS; Shields, RK; Zhao, Y | 1 |
| Kurtinecz, M; Li, G; Mitrani-Gold, FS; Mundy, LM; Singh, KP; Tomayko, JF; Wetherington, J | 1 |
| Arthur, M; Cordillot, M; Dubée, V; Dubost, L; Hugonnet, JE; Mainardi, JL; Marie, A; Triboulet, S | 1 |
| Casari, E; Ferrario, A; Morelli, P; Piazza, A; Tordato, F | 1 |
| Taylor, B; Taylor, SP | 1 |
| Clancy, CJ; Doi, Y; Nguyen, MH; O'Hara, JA; Oleksiuk, LM; Press, EG; Shields, RK; Updike, CL | 1 |
| Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB | 1 |
| Aubry, A; Bréchot, N; Brisson, H; Brossier, F; Chastre, J; Combes, A; Jarlier, V; Lu, Q; Luyt, CE; Micaelo, M; Rouby, JJ; Trouillet, JL | 1 |
| Hagiwara, K; Hirama, T; Kanazawa, M; Kawana, H; Kawashima, A; Masumoto, A; Mio, T; Nagata, M; Shiono, A | 1 |
| Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Perlin, DS; Shields, RK | 1 |
| Anh, ND; Chan, WM; Garcia, J; Harijanto, E; Lee, C; Loo, CM; Mustafa, M; Van Kinh, N | 1 |
| Kirikae, T; Miyoshi-Akiyama, T; Shimada, K; Tada, T | 1 |
| Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
| Fujita, T; Hata, H; Hieda, M; Hori, Y; Kobayashi, J; Murata, Y; Nakajima, S; Nakatani, T; Sata, M; Sato, T; Seguchi, O; Sunami, H; Wada, K; Watanabe, T; Yanase, M | 1 |
| Igarashi, Y; Inui, K; Ohara, H; Ryozawa, S; Tazuma, S; Tsuyuguchi, T | 1 |
| Azumi, Y; Isaji, S; Kishiwada, M; Mizuno, S; Nobuoka, Y; Osawa, I; Sakurai, H; Tabata, M; Tanemura, A; Usui, M | 1 |
| Ariza, J; Bergen, PJ; Li, J; Lora-Tamayo, J; Luo, X; Murillo, O; Nation, RL; Poudyal, A; Yu, HY | 1 |
| Bulitta, JB; Dunlop, R; Hayashi, Y; Jarrett, P; Lassig-Smith, M; Lipman, J; Roberts, JA; Roberts, NA; Starr, T; Stuart, J; Udy, AA; Wallis, SC | 1 |
| Abbasi, SA; Day, KM; Paterson, DL; Perry, JD; Raza, MW; Sartor, AL; Sidjabat, HE | 1 |
| Colombo, V; Masciocchi, N; Palmisano, G | 1 |
| Gaszynski, T; Gaszynski, W; Tokarz, A; Wieczorek, A | 1 |
| Bulitta, JB; Cheah, SE; Li, J; Nation, RL | 1 |
| Herodes, K; Karjagin, J; Kern, H; Kipper, K; Low, K; Metsvaht, T; Oselin, K; Standing, JF; Starkopf, J; Tamme, K | 1 |
| Abe, J; Fujita, A; Hino, M; Hirose, A; Kakeya, H; Kaneko, Y; Nakaie, K; Nakamura, Y; Okada, Y; Takizawa, E; Yamada, K | 1 |
| Black, DJ; Frase, H; Smith, CA; Stewart, NK; Vakulenko, SB | 1 |
| Ishibashi, T; Kubota, R; Matsuo, Y; Wajima, T | 1 |
| Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M | 1 |
| Chen, L; Clancy, CJ; Clarke, LG; Eschenauer, GA; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
| Adler, B; Aranda, J; Boyce, JD; Crane, B; Deveson Lucas, D; Harper, M; Harrison, P; Henry, R; Li, J; Li, Z; Nation, RL; Powell, D | 1 |
| Hara, T; Horiyama, T; Izawa, M; Kanazawa, S; Maki, H; Sato, T; Tsuji, M; Yamaguchi, T | 1 |
| Bergen, PJ; Bulitta, JB; Forrest, A; Holden, PN; Landersdorfer, CB; Li, J; Ly, NS; Nation, RL; Rao, GG; Tsuji, BT | 1 |
| Ahmed, SS; Alp, E; Demiraslan, H; Dinc, G; Doganay, M; Elmali, F | 1 |
| Liu, W; Miao, J; Qin, YP; Shu, SQ; Wang, Y; Zhang, L; Zheng, J | 1 |
| Ishibashi, T; Matsuo, Y; Shimamura, K; Wajima, T | 1 |
| Ikawa, K; Ishihara, N; Isobe, T; Karino, F; Miura, K; Morikawa, N; Naora, K; Nishimura, N; Tamaki, H | 1 |
| Carlson, EE; Kocaoglu, O; Tsui, HC; Winkler, ME | 1 |
| Li, Y; Liu, J; Lv, Y; Xue, F; Zhang, J; Zheng, B | 1 |
| Allegaert, K; Bradley, JS; Castaneda-Ruiz, B; Cirillo, I; Cossey, V; Redman, R; Vaccaro, N | 1 |
| Barauskas, V; Bradley, JS; Cannavino, CR; Castaneda-Ruiz, B; Cirillo, I; Emeryk, A; Go, O; Redman, R; Senatorova, G | 1 |
| Kaushik, A; Lamichhane, G; Makkar, N; Pandey, P; Parrish, N; Singh, U | 1 |
| Anh, NQ; Kirikae, T; Miyoshi-Akiyama, T; Nhung, PH; Ohmagari, N; Phuong, DM; Shimada, K; Tada, T | 1 |
| Anupurba, S; Banerjee, T; Filgona, J | 1 |
| Ansari, M; Gilani, M; Hafeez, A; Latif, M; Munir, T; Najeeb, S; Rehman, S; Saad, N | 1 |
| Abd Rahman, AN; Abdul-Aziz, MH; Lipman, J; Mat-Nor, MB; Roberts, JA; Staatz, CE; Sulaiman, H; Wallis, SC | 1 |
| Garcia, CV; Mendez, AS; Paliosa, PK; Schapoval, EE; Steppe, M | 1 |
| Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC | 1 |
| Choi, IS; Choi, JA; Jang, SJ; Jeong, SH; Kang, SH; Kim, CM; Moon, DS; Park, G; Park, GC | 1 |
| Srinivas, NR | 1 |
| Fritsch, A; Jaehde, U; Jäger, W; Jilch, S; Lemmerer, R; Maier-Salamon, A; Saria, K; Thalhammer, F; Unger, M; Vossen, MG; Wenisch, JM; Zuba, C | 1 |
| Asık, G; Atasoy, AR; Aykan, SB; Ciftci, IH; Karakece, E; Terzi, HA | 1 |
| Ji, S; Li, C; Li, S; Liang, X; Zhang, F; Zhu, Y | 1 |
| Akata, K; Ishimoto, H; Kawanami, T; Kido, T; Mukae, H; Naito, K; Nishida, C; Noguchi, S; Sakamoto, N; Yamasaki, K; Yatera, K | 1 |
| Baron, C; Bulitta, JB; Bulman, ZP; Holden, PN; Li, J; Ly, NS; Rao, GG; Sutton, MD; Tsuji, BT | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Maitte, A; Potel, G | 1 |
| Mirza, IA; Wali, N | 1 |
| Arakawa, Y; Jin, W; Kimura, K; Kurosaki, H; Mori, S; Wachino, J; Yamaguchi, Y | 1 |
| Abdollahi, A; Aliramezani, A; Boroumand, MA; Douraghi, M; Ghalavand, Z; Ghourchian, S; Mohammadzadeh, M; Nateghi Rostami, M; Rahbar, M; Zeraati, H | 1 |
| Ishihara, T; Miyazaki, M; Notani, N; Tsumura, H; Yoshiiwa, T | 1 |
| Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP | 1 |
| Armstrong, J; Gasink, LB; Huang, X; Newell, P; Sobel, JD; Stone, GG; Wagenlehner, FM; Yates, K | 1 |
| Fujiya, Y; Hayakawa, K; Kutsuna, S; Mawatari, M; Mezaki, K; Nagamatsu, M; Ohmagari, N; Takeshita, N; Tamura, S; Yamamoto, K | 1 |
| Li, F; Li, P; Yin, Y; Zhang, Q; Zhang, Y | 1 |
| Hu, YF; Liu, CP; Shih, SC; Wang, NY | 1 |
| Badal, RE; Biedenbach, DJ; Giao, PT; Hung Van, P; Phuong, DM; Su Minh Tuyet, N; Thi Thanh Nga, T; Vu Trung, N | 1 |
| June, CM; Klamer, ZL; Leonard, DA; Muckenthaler, TJ; Powers, RA; Schroder, EC; Szarecka, A; Wawrzak, Z | 1 |
| Abraham, P; Chaar, M; Chester, K; Curzio, K; Huang, V; Lockwood, A; Lodise, TP; Morse, B; Pai, MP; Patka, J; Rabinovich, M; Rahbar, AJ; Salomone, J; Williams, B | 1 |
| Chao, CM; Chen, CC; Chuang, YC; Huang, HL; Lai, CC; Tang, HJ | 1 |
| Haruyama, S; Nakamura, M; Ohmori, S; Okada, E; Sawada, Y; Shibata, M; Yamaguchi, T; Yoshioka, M | 1 |
| Ajao, AO; Albrecht, JS; Furuno, JP; Harris, AD; Johnson, JK; Pineles, LL; Robinson, GL; Thom, KA; Zhao, L | 1 |
| Cheatham, SC; Chung, EK; Fleming, MR; Kays, MB | 1 |
| Cancelli, F; Castaldi, D; Ciardi, MR; Cipolla, A; D'Abramo, A; D'Agostino, C; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Scorzolini, L; Vullo, V | 1 |
| Goto, K; Ito, K; Itoh, H; Kaneko, T; Kurogi, S; Nonoshita, K; Ohchi, Y; Sato, Y; Suzuki, Y; Tanaka, R; Ueno, T; Yasuda, N | 1 |
| Aydin, M; Bayram, S; Bozkurt, O; Genç, A; Rencüzoğullari, E | 1 |
| Bonomo, RA; Harper, TM; June, CM; Leonard, DA; Powers, RA; Taracila, MA | 1 |
| Aubry, A; Bréchot, N; Brossier, F; Jarlier, V; Lu, Q; Luyt, CE; Micaëlo, M; Monsel, A | 1 |
| Smith, CA; Stewart, NK; Toth, M; Vakulenko, SB | 1 |
| Jeyakanthan, J; Lopes, BS; Ramachandran, B | 1 |
| Allison, N; Crisostomo, C; Lynch, B; Padilla, M; Quach-Cu, J; Reinke, RA | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 1 |
| Eom, YB; Kim, HR | 1 |
| Chang, H; Lee, CM; Lee, MC; Lu, CH; Sun, FJ; Wu, AY | 1 |
| Ishaq, M; Zahra, N; Zeshan, B | 1 |
| Dargahi, Z; Etemad, A; Ghasemian, E; Hashemian, M; Kaviar, VH; Lohrasbi, A; Saadh, MJ | 1 |
| George Priya Doss, C; Gopikrishnan, M | 1 |
| Asai, Y; Ooi, H; Sato, Y | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
39 review(s) available for carbapenems and doripenem
| Article | Year |
|---|---|
Doripenem: S 4661.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Stability; Humans | 2003 |
Doripenem.
Topics: Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic | 2006 |
Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Biofilms; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Immunocompromised Host; Minocycline; Pseudomonas aeruginosa; Pseudomonas Infections; Tigecycline | 2006 |
Comparative review of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Thienamycins | 2007 |
Empiric treatment options in the management of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Carbapenems; Community-Acquired Infections; Cross Infection; Doripenem; Drug Resistance, Bacterial; General Surgery; Humans; Internal Medicine; Minocycline; Peritoneal Cavity; Peritonitis; Risk Factors; Severity of Illness Index; Surgical Wound Infection; Tigecycline | 2007 |
Carbapenems in the USA: focus on doripenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Structure-Activity Relationship; Thienamycins; United States | 2007 |
Carbapenems: a potent class of antibiotics.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Carbapenems; Clinical Trials as Topic; Doripenem; Ertapenem; Humans; Imipenem; Meropenem; Molecular Structure; Structure-Activity Relationship; Thienamycins | 2008 |
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Meropenem; Patient Selection; Pneumonia, Bacterial; Respiratory Tract Infections; Severity of Illness Index; Thienamycins; Treatment Outcome | 2008 |
Current therapies for pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic | 2008 |
Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Drug Evaluation; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Molecular Structure | 2008 |
Doripenem: a review of its use in the treatment of bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Drug Interactions; Drug Resistance, Bacterial; Humans; Kidney Diseases; Tissue Distribution | 2008 |
What's new and not so new on the antimicrobial horizon?
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Cephalosporins; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Pyrimidines; Research | 2008 |
Doripenem: a new addition to the carbapenem class of antimicrobials.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Urinary Tract Infections | 2009 |
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Interactions; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests | 2009 |
Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Clinical Trials as Topic; Doripenem; Humans; Microbial Sensitivity Tests; Rats | 2009 |
Doripenem: antimicrobial profile and clinical potential.
Topics: Bacteria; Bacterial Infections; Carbapenems; Doripenem; Humans | 2009 |
Doripenem: position in clinical practice.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Cross Infection; Doripenem; Drug Interactions; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas Infections | 2009 |
Doripenem.
Topics: Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Peritonitis; Pneumonia, Bacterial; Seizures; Urinary Tract Infections | 2009 |
Doripenem: a new carbapenem in the treatment of nosocomial infection.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Overview of seizure-inducing potential of doripenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Seizures; Young Adult | 2009 |
Multidrug-resistant Gram-negative infections: what are the treatment options?
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Minocycline; Polymyxins; Tigecycline | 2009 |
Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2009 |
[Doripenem: need for a new carbapenem].
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia; Carbapenems; Clinical Trials as Topic; Cross Infection; Doripenem; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Humans; Nervous System Diseases; Peritonitis; Pneumonia, Bacterial; Pseudomonas aeruginosa; Urinary Tract Infections | 2009 |
Doripenem versus bacteria: an emerging battleground.
Topics: Animals; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Humans | 2009 |
[Update on antimicrobial chemotherapy].
Topics: Acetamides; Aminoglycosides; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Daptomycin; Doripenem; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; France; Humans; Linezolid; Lipoglycopeptides; Minocycline; Oxazolidinones; Penicillins; Pyrimidines; Teicoplanin; Tigecycline | 2010 |
Doripenem: an early look at a carbapenem not yet approved for pediatrics.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Humans; Microbial Sensitivity Tests | 2010 |
Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cystic Fibrosis; Doripenem; Humans; Minocycline; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus aureus; Stenotrophomonas maltophilia; Tigecycline | 2010 |
The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Humans | 2010 |
In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; France; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitals, Teaching; Humans; Microbial Sensitivity Tests | 2011 |
Doripenem: a new carbapenem antibiotic.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Drug Interactions; Drug Resistance, Bacterial; Formularies, Hospital as Topic; Humans | 2010 |
[Role of new carbapenems in nosocomial intraabdominal infection].
Topics: Abdomen; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Humans; Multicenter Studies as Topic; Postoperative Complications; Pseudomonas Infections; Randomized Controlled Trials as Topic; Soft Tissue Infections | 2010 |
Multiresistant bacteria and current therapy - the economical side of the story.
Topics: Acetamides; Anti-Bacterial Agents; Carbapenems; Daptomycin; Doripenem; Drug Resistance, Microbial; Drug Resistance, Multiple; Economics, Pharmaceutical; Linezolid; Minocycline; Oxazolidinones; Tigecycline | 2010 |
Carbapenems: past, present, and future.
Topics: Anti-Bacterial Agents; beta-Alanine; beta-Lactams; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Thienamycins | 2011 |
In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli.
Topics: Anti-Bacterial Agents; Bacillus; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2011 |
A case of Lemierre's syndrome in association with liver abscess without any other metastatic lesions.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Disseminated Intravascular Coagulation; Doripenem; Fusobacterium necrophorum; Humans; Lemierre Syndrome; Liver Abscess; Male; Ofloxacin | 2012 |
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Databases, Bibliographic; Doripenem; Drug Combinations; Female; Humans; Imipenem; Levofloxacin; Male; Research Design; Treatment Outcome; Urinary Tract Infections | 2013 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
32 trial(s) available for carbapenems and doripenem
| Article | Year |
|---|---|
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Models, Statistical; Monte Carlo Method | 2005 |
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Topics: Aged; Anti-Bacterial Agents; APACHE; Carbapenems; Doripenem; Female; Hospital Mortality; Humans; Imipenem; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Treatment Outcome | 2008 |
"The truth, if it exists, is in the details".
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Pneumonia, Ventilator-Associated; Severity of Illness Index; Treatment Outcome | 2008 |
Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Costs and Cost Analysis; Doripenem; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hospital Costs; Humans; Imipenem; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Ventilator-Associated; Survival Rate; Treatment Outcome | 2008 |
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Tazobactam; Treatment Outcome | 2008 |
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Male; Meropenem; Middle Aged; Prospective Studies; Thienamycins | 2008 |
Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbapenems; Carbon Radioisotopes; Chromatography, Liquid; Cohort Studies; Doripenem; Humans; Infusions, Intravenous; Male; Middle Aged; Safety; Tandem Mass Spectrometry | 2008 |
[Clinical examination of doripenem for infectious diseases in gynecological and associated fields].
Topics: Bacterial Infections; Carbapenems; Doripenem; Female; Genital Diseases, Female; Humans; Infusions, Intravenous; Pregnancy; Pregnancy Complications, Infectious; Puerperal Infection; Treatment Outcome | 2008 |
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Pyelonephritis; Urinary Tract Infections | 2009 |
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cross-Over Studies; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Time Factors | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pyelonephritis; Urinary Tract Infections | 2009 |
Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bayes Theorem; Carbapenems; Creatinine; Critical Illness; Cross Infection; Doripenem; Female; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nonlinear Dynamics; Pneumonia, Bacterial; Pyelonephritis; Renal Insufficiency; Urinary Tract Infections; Young Adult | 2010 |
Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.
Topics: Adult; Aged; Carbapenems; Doripenem; Hemodiafiltration; Hemofiltration; Humans; Male; Middle Aged | 2011 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pyelonephritis; Treatment Outcome; Urinary Tract Infections | 2010 |
Penetration of intact blood-brain barrier by doripenem.
Topics: Anti-Bacterial Agents; Blood-Brain Barrier; Carbapenems; Doripenem; Humans; Injections, Spinal | 2011 |
Validation of doripenem dosing in patients with end-stage renal disease receiving hemodialysis.
Topics: Carbapenems; Doripenem; Female; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis | 2011 |
Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Young Adult | 2012 |
A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Female; Fever; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Risk Factors; Thienamycins; Treatment Outcome | 2012 |
Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Time Factors | 2012 |
Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Gram-Negative Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Neutropenia; Young Adult | 2012 |
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Doripenem; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Ventilator-Associated; Young Adult | 2012 |
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Cross Infection; Doripenem; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Middle Aged; Monte Carlo Method; Obesity; Pneumonia, Bacterial | 2013 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem; Intraabdominal Infections; Male; Meropenem; Ofloxacin; Pneumonia; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Gram-Negative Bacteria; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity; Thienamycins | 2014 |
Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Thienamycins | 2014 |
A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study).
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Intensive Care Units; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome; Urinary Tract Infections; Young Adult | 2014 |
Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Body Temperature; C-Reactive Protein; Carbapenems; Cholangitis; Cholecystitis, Acute; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Treatment Outcome; Young Adult | 2015 |
Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Middle Aged; Monte Carlo Method; Shock, Septic | 2015 |
Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.
Topics: Anti-Bacterial Agents; Area Under Curve; Carbapenems; Doripenem; Female; Gestational Age; Half-Life; Humans; Infant; Infant, Newborn; Infant, Premature; Infusions, Intravenous; Male | 2015 |
Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Preschool; Doripenem; Hospitalization; Humans; Infant; Intraabdominal Infections; Pneumonia, Bacterial; Treatment Outcome; Urinary Tract Infections | 2015 |
Doripenem Treatment during Continuous Renal Replacement Therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Critical Care; Doripenem; Female; Hemodiafiltration; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis | 2015 |
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Topics: Adult; Aged; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Doripenem; Drug Combinations; Female; Humans; Male; Middle Aged; Pyelonephritis; Urinary Tract Infections | 2016 |
256 other study(ies) available for carbapenems and doripenem
| Article | Year |
|---|---|
A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Positive Bacteria; Magnetic Resonance Spectroscopy; Spectrophotometry, Infrared; Structure-Activity Relationship | 1996 |
Synthesis and modification of a novel 1 beta-methyl carbapenem antibiotic, S-4661.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Microbial Sensitivity Tests; Stereoisomerism; Structure-Activity Relationship | 1996 |
Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I.
Topics: Anti-Bacterial Agents; Carbapenems; Dipeptidases; Doripenem; Drug Stability; Humans; Lactams; Recombinant Proteins | 1996 |
In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Doripenem; Enterobacteriaceae; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Moraxella; Penicillin Resistance; Pneumococcal Infections | 1998 |
In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Microbial Sensitivity Tests; Rats; Uterine Diseases | 2000 |
In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Ceftazidime; Doripenem; Humans; Imipenem; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Thienamycins; Urinary Tract Infections | 2002 |
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Conjugation, Genetic; Doripenem; Enterobacteriaceae; Escherichia coli; Klebsiella; Microbial Sensitivity Tests; Plasmids | 2004 |
In vitro antimicrobial activity of doripenem, a new carbapenem.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Cephalosporins; Doripenem; Drug Therapy, Combination; Enterobacteriaceae; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 2004 |
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Culture Media; Doripenem; Enterobacteriaceae; Enterococcus; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quality Control; Respiratory Tract Infections | 2004 |
Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Carbapenems; Conjugation, Genetic; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2004 |
Activities of doripenem (S-4661) against drug-resistant clinical pathogens.
Topics: Bacteria; Bacterial Infections; Carbapenems; Doripenem; Drug Resistance, Bacterial; Genotype; Gram-Negative Bacteria; Humans; Phenotype | 2004 |
Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control.
Topics: Carbapenems; Diffusion; Doripenem; Microbial Sensitivity Tests; Quality Control | 2005 |
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Doripenem; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 2005 |
Antibacterial Drug Discovery and Development Summit - Tenth Annual SRI Summit.
Topics: Anti-Bacterial Agents; Biofilms; Carbapenems; Clinical Trials as Topic; Doripenem; Drug Design; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Iohexol; Macrolides; Microsomes; Minocycline; Technology, Pharmaceutical; Tigecycline | 2005 |
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
Acquisitions not a cure for anti-infectives.
Topics: Anidulafungin; Anti-Infective Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Drug Industry; Echinocandins; Economics, Pharmaceutical; Glycopeptides; Humans; Peptides, Cyclic; Teicoplanin | 2005 |
In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Thienamycins | 2005 |
Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Japan; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Vancomycin | 2005 |
Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Positive Cocci; Gram-Positive Rods; Humans; Microbial Sensitivity Tests; Population Surveillance; Respiratory System | 2005 |
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Burkholderia cepacia; Carbapenems; Cystic Fibrosis; Doripenem; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2006 |
[A new carbapenem antibiotic for injection: characteristics of doripenem].
Topics: Carbapenems; Doripenem; Humans; Injections | 2005 |
Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
Topics: Alanine; Animals; Anti-Bacterial Agents; Anticonvulsants; Carbapenems; Convulsants; Dogs; Doripenem; Drug Interactions; Electroencephalography; Injections, Intravenous; Injections, Intraventricular; Male; Meropenem; Mice; Mice, Inbred ICR; Pentylenetetrazole; Rats; Rats, Wistar; Seizures; Thienamycins; Valproic Acid | 2006 |
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
Topics: Aminoglycosides; beta-Lactam Resistance; beta-Lactams; Carbapenems; Doripenem; Drug Interactions; Gentamicins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2006 |
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Polyacrylamide Gel; Gene Expression; Imipenem; Meropenem; Molecular Weight; Mutation; Pseudomonas aeruginosa; Thienamycins | 2006 |
Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ceftazidime; Doripenem; Humans; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2006 |
Development of an HPLC method for the determination of doripenem in human and mouse serum.
Topics: Animals; Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Humans; Mice; Reproducibility of Results | 2007 |
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients.
Topics: Abdomen; Adult; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Doripenem; Exudates and Transudates; Female; Humans; Injections, Intravenous; Male; Middle Aged; Peritoneum | 2007 |
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Colony Count, Microbial; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
Topics: Anti-Bacterial Agents; Biomarkers; Carbapenems; Doripenem; Drug Approval; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Oxacillin; United States; United States Food and Drug Administration | 2007 |
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Diabetic Foot; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
Doripenem (Doribax)--a new parenteral carbapenem.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Drug Administration Schedule; Drug Interactions; Humans; Infusions, Intravenous; Pneumonia, Ventilator-Associated; Treatment Outcome; Urinary Tract Infections | 2008 |
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x.
Topics: Aminoacyltransferases; Bacterial Proteins; beta-Lactams; Carbapenems; Doripenem; Humans; Mutation; Penicillin-Binding Proteins; Penicillins; Peptidyl Transferases; Protein Binding; Protein Structure, Tertiary; Streptococcus pneumoniae; United States | 2008 |
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Carbapenems; Doripenem; Escherichia coli; Escherichia coli Proteins; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Pseudomonas aeruginosa | 2008 |
Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection.
Topics: Ascitic Fluid; Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Humans; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2008 |
[Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Meropenem; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2007 |
Doripenem (doribax)--a new parenteral carbapenem.
Topics: Carbapenems; Cross Infection; Doripenem; Female; Humans; Pneumonia; Pneumonia, Ventilator-Associated; Urinary Tract Infections | 2008 |
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Compatibility of doripenem with other drugs during simulated Y-site administration.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Incompatibility; Injections, Intravenous; Nephelometry and Turbidimetry | 2008 |
New drugs08, part 2.
Topics: Acromegaly; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antineoplastic Agents; Biopterins; Carbapenems; Child; Child, Preschool; Cyclohexanes; Doripenem; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Epothilones; Humans; Infant; Maraviroc; Peptides, Cyclic; Pharmaceutical Preparations; Phenylketonurias; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sirolimus; Somatostatin; Triazoles | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.
Topics: Adult; Algorithms; Anti-Bacterial Agents; Ascitic Fluid; Carbapenems; Doripenem; Female; Gram-Negative Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Surgical Wound Infection; Young Adult | 2008 |
Doripenem: a new carbapenem.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Humans | 2008 |
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; United States | 2008 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Doripenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2009 |
Lucasti et al in the May 2008 issue of Clinical Therapeutics.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Thienamycins | 2008 |
Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Computer Simulation; Doripenem; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Plasma; Time Factors; Urine | 2009 |
Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Topics: Anti-Bacterial Agents; Carbapenems; Chromatography, High Pressure Liquid; Cold Temperature; Dimerization; Doripenem; Drug Contamination; Drug Packaging; Drug Stability; Drug Storage; Glucose; Humans; Hydrogen-Ion Concentration; Infusions, Parenteral; Injections; Molecular Structure; Particle Size; Pharmaceutical Solutions; Sodium Chloride; Time Factors | 2008 |
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests | 2009 |
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Topics: Acinetobacter; Aeromonas; Anti-Bacterial Agents; Bacteria, Aerobic; Carbapenems; Doripenem; Gram-Negative Bacterial Infections; Humans; Latin America; Microbial Sensitivity Tests; North America; Pseudomonas | 2009 |
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Clinical Trials as Topic; Computer Simulation; Critical Illness; Doripenem; Female; Humans; Mice | 2009 |
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2009 |
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Topics: Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Enterococcus; Europe; Gram-Positive Bacterial Infections; Humans; Latin America; Microbial Sensitivity Tests; North America; Staphylococcus; Streptococcus | 2009 |
In vitro activity of doripenem against Burkholderia pseudomallei.
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Carbapenems; Doripenem; Microbial Sensitivity Tests | 2009 |
Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Encephalitis; Humans; Imipenem; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Doripenem-induced intertriginous drug eruption as a mild form of AGEP.
Topics: Anti-Bacterial Agents; Axilla; Carbapenems; Doripenem; Epiglottitis; Exanthema; Groin; Humans; Leg; Male; Middle Aged | 2009 |
In vitro activity of doripenem.
Topics: Anti-Bacterial Agents; Carbapenems; Culture Media; Doripenem; Drug Therapy, Combination; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2009 |
Efficacy of intravenous infusion of doripenem.
Topics: Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2009 |
Safety of intravenous infusion of doripenem.
Topics: Anti-Bacterial Agents; Area Under Curve; Carbapenems; Cross Infection; Doripenem; Drug Stability; Drug-Related Side Effects and Adverse Reactions; Humans; Hypersensitivity; Infusions, Intravenous; Injections, Intravenous; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Quality Control | 2009 |
Clinical and economic consequences of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Health Care Costs; Hospital Mortality; Humans; Imipenem; Intensive Care Units; Length of Stay; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Severity of Illness Index | 2009 |
Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
Topics: beta-Lactamase Inhibitors; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Doripenem; Drug Utilization; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Statistics as Topic; Thienamycins | 2009 |
Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Health Facilities; Humans; Japan; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Carbapenems; Doripenem; Enzyme Inhibitors; Hydrolysis; Imipenem; Kinetics; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2010 |
Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Humans; Pneumonia; United States | 2010 |
Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.
Topics: Anti-Bacterial Agents; Carbapenems; Computer Simulation; Doripenem; Dose-Response Relationship, Drug; Drug Administration Schedule; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Pseudomonas aeruginosa | 2010 |
The 1.4 A crystal structure of the class D beta-lactamase OXA-1 complexed with doripenem.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Carboxylic Acids; Catalytic Domain; Crystallization; Crystallography, X-Ray; Doripenem; Enzyme Stability; Ligands; Models, Molecular | 2009 |
The changing face of antibiotic therapy.
Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Delayed-Action Preparations; Doripenem; Drug Resistance, Bacterial; Humans; Infection Control; Treatment Outcome | 2009 |
Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
Topics: Aged; Aged, 80 and over; Carbapenems; Critical Illness; Doripenem; Female; Half-Life; Hemodiafiltration; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Renal Insufficiency | 2010 |
Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cost-Benefit Analysis; Decision Support Techniques; Doripenem; Hospitalization; Humans; Imipenem; Intensive Care Units; Length of Stay; Middle Aged; Models, Economic; Monte Carlo Method; Pneumonia, Ventilator-Associated; Probability; Respiration, Artificial; Time Factors; United States | 2010 |
Stability of meropenem and doripenem solutions for administration by continuous infusion.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Humans; Infusions, Intravenous; Meropenem; Solutions; Thienamycins | 2010 |
Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Chromatography; Doripenem; Humans; Infusions, Intravenous; Male; Middle Aged; Prostate; Prostatectomy; Serum | 2010 |
Potential of doripenem for the treatment of infections with multidrug-resistant Pseudomonas spp.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Japan; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections | 2010 |
[Activity of doripenem against Pseudomonas spp. and Acinetobacter spp. rods].
Topics: Acinetobacter; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Pseudomonas; Species Specificity | 2009 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Mutation; Porins; Proportional Hazards Models; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2010 |
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Mutation; Phenotype; Pseudomonas aeruginosa; Thienamycins | 2010 |
Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Topics: Acinetobacter baumannii; beta-Lactamases; Carbapenems; Doripenem; Genotype; Hospitals; Humans; Imipenem; Meropenem; Oxytocin; Polymerase Chain Reaction; Thienamycins | 2010 |
Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem.
Topics: beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Crystallization; Crystallography, X-Ray; Cyclotrons; Doripenem; Ertapenem; Fourier Analysis; Hydrogen Bonding; Indicators and Reagents; Kinetics; Mass Spectrometry; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Protein Conformation | 2010 |
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin | 2010 |
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Doripenem; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method | 2010 |
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2010 |
Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing method.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; European Union; Humans; Microbial Sensitivity Tests | 2010 |
Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
[Activity of doripenem against anaerobic bacteria].
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Microbial; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Humans; Imipenem; Microbial Sensitivity Tests | 2011 |
Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2010 |
A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
Topics: Anti-Bacterial Agents; Bacteremia; Bile Duct Diseases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Liver Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2010 |
The UV-derivative spectrophotometry for the determination of doripenem in the presence of its degradation products.
Topics: Calibration; Carbapenems; Doripenem; Limit of Detection; Molecular Structure; Pharmaceutical Preparations; Solutions; Spectrophotometry, Ultraviolet; Water | 2010 |
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Humans; Immunocompetence; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Thigh | 2010 |
Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Doripenem; Drug Combinations; Humans; Imipenem; Length of Stay; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Young Adult | 2010 |
Stability of doripenem, imipenem and meropenem at elevated room temperatures.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Stability; Drug Storage; Imipenem; Meropenem; Temperature; Thienamycins; Time Factors | 2011 |
Antimicrobial activity of doripenem against bacterial isolates from humans and animals.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Enterococcus faecalis; Enterococcus faecium; Escherichia coli; Humans; Microbial Sensitivity Tests; Portugal | 2010 |
Stability of doripenem in polyvinyl chloride bags and elastomeric pumps.
Topics: Anti-Bacterial Agents; Carbapenems; Chemical Precipitation; Doripenem; Drug Packaging; Drug Stability; Drug Storage; Elastomers; Freezing; Glucose; Humans; Pharmaceutical Vehicles; Polyvinyl Chloride; Refrigeration; Sodium Chloride; Temperature; Time Factors | 2010 |
[Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Enterobacteriaceae Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas Infections; Spain; Thienamycins | 2010 |
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Carbapenems; Disease Models, Animal; Doripenem; Female; Imipenem; Infusions, Intravenous; Lung; Meropenem; Plasma; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Spleen; Thienamycins; Treatment Outcome | 2010 |
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Topics: Anti-Bacterial Agents; Asia; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins | 2010 |
Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Korea; Meropenem; Microbial Sensitivity Tests; Republic of Korea; Thienamycins; Urinary Tract Infections | 2011 |
In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Male; Meropenem; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Specific Pathogen-Free Organisms; Thienamycins | 2011 |
Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Doripenem; Drug Therapy, Combination; Female; Fosfomycin; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa | 2010 |
Nosocomial infections: new therapeutic alternatives.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic | 2010 |
Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; Carbapenems; Cytokines; Disease Models, Animal; Doripenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 2011 |
Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Topics: Anti-Bacterial Agents; Asia; Australia; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intravenous; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Thienamycins | 2011 |
In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Carbapenems; Doripenem; Humans; Microbial Sensitivity Tests | 2011 |
Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem.
Topics: Acinetobacter baumannii; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Crystallography, X-Ray; Doripenem; Models, Molecular; Mutant Proteins; Mutation, Missense; Protein Structure, Tertiary | 2011 |
Potential interaction between valproic acid and doripenem.
Topics: Adolescent; Carbapenems; Doripenem; Drug Interactions; Female; Humans; Valproic Acid | 2011 |
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2011 |
Determination of doripenem and related substances in medicinal product using capillary electrophoresis.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Electrophoresis, Capillary; Pharmaceutical Preparations | 2011 |
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Doripenem; Electrophoresis, Gel, Pulsed-Field; Ertapenem; Genotype; Hospitals, Urban; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phylogeny; Polymerase Chain Reaction; Sensitivity and Specificity; Thienamycins; United States | 2011 |
Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Microbial Sensitivity Tests; Minocycline; Nocardia; Quinolones; RNA, Ribosomal, 16S; Tigecycline | 2011 |
Comparative activity of carbapenem testing: the COMPACT study.
Topics: Africa; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle East; Thienamycins | 2011 |
Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rectum; Stenotrophomonas maltophilia; Thienamycins | 2011 |
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Burkholderia pseudomallei; Carbapenems; Doripenem; Ertapenem; Fluoroquinolones; Humans; Melioidosis; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Edetic Acid; Humans; Imipenem; Laboratories; Meropenem; Microbial Sensitivity Tests; Netherlands; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thienamycins | 2011 |
Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis | 2011 |
[Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Turkey | 2011 |
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Plasmids; Population Surveillance; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Spain; Thienamycins | 2011 |
Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Genotype; Imipenem; Klebsiella pneumoniae; Longitudinal Studies; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Thienamycins; United States | 2011 |
Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex.
Topics: Acinetobacter baumannii; Acinetobacter calcoaceticus; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2011 |
In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Streptococcus pneumoniae; Thienamycins | 2011 |
Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration.
Topics: Aged; Aged, 80 and over; Carbapenems; Chromatography, High Pressure Liquid; Critical Illness; Doripenem; Female; Hemodiafiltration; Humans; Kidney Diseases; Male; Middle Aged; Severity of Illness Index; Time Factors | 2011 |
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Colony Count, Microbial; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Half-Life; Humans; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Evaluation of doripenem utilization and susceptibilities at a large urban hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Treatment Failure; Treatment Outcome; Urban Health Services; Young Adult | 2011 |
[In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Ciprofloxacin; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tobramycin | 2011 |
Two cases of peritonsillar abscess complicated by von Willebrand disease.
Topics: Anti-Bacterial Agents; Carbapenems; Coagulants; Doripenem; Factor VIII; Female; Humans; Male; Middle Aged; Peritonsillar Abscess; Tonsillectomy; von Willebrand Disease, Type 2; von Willebrand Diseases; Young Adult | 2012 |
Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Extracellular Fluid; Humans; Infusions, Intravenous; Male; Microdialysis; Muscle, Skeletal; Plasma; Saliva; Subcutaneous Fat; Tandem Mass Spectrometry; Tissue Distribution | 2012 |
Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Cefepime; Cephalosporins; Disease Models, Animal; Doripenem; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Meningitis, Bacterial; Rabbits; Treatment Outcome | 2012 |
Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Humans; Imipenem; Lung; Meropenem; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Thienamycins; Treatment Outcome | 2012 |
Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Topics: Anti-Bacterial Agents; Area Under Curve; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Models, Biological; Mutation; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Reference Standards; Thienamycins | 2012 |
Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Topics: Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Germany; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quality Control; Thienamycins | 2012 |
Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.
Topics: Carbapenems; Colistin; Cross Infection; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fosfomycin; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Retrospective Studies; Time Factors | 2012 |
Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Brain; Brain Injuries; Carbapenems; Doripenem; Female; Humans; Male; Microbial Sensitivity Tests; Microdialysis; Middle Aged; Plasma; Time Factors | 2012 |
Successful treatment with doripenem of ventriculitis due to Achromobacter xylosoxidans.
Topics: Achromobacter denitrificans; Adult; Anti-Bacterial Agents; Carbapenems; Cerebral Ventriculitis; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Treatment Outcome | 2014 |
The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Combinations; Drug Interactions; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Doripenem; Humans; Models, Statistical; Plasma | 2012 |
Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Topics: Animals; beta-Lactams; Carbapenems; Cell Line; Doripenem; Ertapenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Salmonella; Thienamycins | 2012 |
What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Critical Illness; Cross Infection; Doripenem; Humans; Kidney; Metabolic Clearance Rate; Pneumonia; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic | 2012 |
Modeling approach to characterize intraocular doripenem pharmacokinetics after intravenous administration to rabbits, with tentative extrapolation to humans.
Topics: Animals; Aqueous Humor; Carbapenems; Doripenem; Humans; Infusions, Intravenous; Rabbits; Vitreous Body | 2012 |
Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.
Topics: Aged; Anti-Bacterial Agents; Carbapenems; Computer Simulation; Doripenem; Humans; Male; Microbial Sensitivity Tests; Monte Carlo Method; Prostate; Prostatitis; Tissue Distribution | 2012 |
Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Doripenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2012 |
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Synergism; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2012 |
OXA-162, a novel variant of OXA-48 displays extended hydrolytic activity towards imipenem, meropenem and doripenem.
Topics: beta-Lactamases; Biocatalysis; Carbapenems; Cloning, Molecular; DNA Transposable Elements; Doripenem; Drug Resistance, Bacterial; Humans; Hydrolysis; Imipenem; Klebsiella pneumoniae; Meropenem; Models, Molecular; Plasmids; Thienamycins | 2013 |
Doripenem: excess mortality.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Early Termination of Clinical Trials; Evidence-Based Medicine; Humans; Imipenem; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
[Septic shock following flexible transurethral lithotripsy showing favourable response after multidisciplinary treatment mainly composed of recombinant thrombomodulin : a case report].
Topics: Aged; Carbapenems; Combined Modality Therapy; Doripenem; Female; Humans; Lithotripsy; Recombinant Proteins; Shock, Septic; Thrombomodulin; Treatment Outcome | 2012 |
Clinical usefulness of doripenem (DRPM), a carbapenem antimicrobial drug, for the treatment of patients with acute cholangitis: retrospective study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Carbapenems; Cholangitis; Doripenem; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2013 |
Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Hospitals, University; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Taiwan; Thienamycins | 2012 |
Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pacific Islands; Thienamycins; Time Factors | 2013 |
Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.
Topics: Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Doripenem; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Time Factors | 2013 |
[Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Culture Media; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Multiplex Polymerase Chain Reaction; Rectum; Sensitivity and Specificity; Thienamycins; Time Factors | 2012 |
The use of UV, FT-IR and Raman spectra for the identification of the newest penem analogs: solutions based on mathematic procedure and the density functional theory.
Topics: beta-Lactams; Carbapenems; Doripenem; Models, Molecular; Quantum Theory; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Thienamycins | 2013 |
Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Carbapenems; Doripenem; Enterobacteriaceae; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Poland; Pseudomonas; Species Specificity; Sputum; Thienamycins | 2012 |
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Humans; Liver; Male; Middle Aged; Neutropenia; Prospective Studies; Sepsis | 2012 |
Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Topics: Acinetobacter; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Monobactams; Pseudomonas aeruginosa; Thiazoles; Thienamycins | 2013 |
Prolonged infusion of carbapenems in critically ill patients: time to extend our practice.
Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Doripenem; Female; Humans; Male; Obesity; Pneumonia, Bacterial | 2013 |
Pharmacodynamic variability beyond that explained by MICs.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Mice; Microbial Sensitivity Tests; Monte Carlo Method; Thigh | 2013 |
Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains.
Topics: Acinetobacter baumannii; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Larva; Lipid A; Microbial Sensitivity Tests; Moths; Signal Transduction; Vancomycin | 2013 |
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Thienamycins; Treatment Outcome; Urinary Tract Infections | 2013 |
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Ertapenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Treatment Outcome | 2013 |
In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Fosfomycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2013 |
Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Colistin; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pneumonia, Ventilator-Associated; Treatment Outcome | 2013 |
Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bayes Theorem; Body Mass Index; Carbapenems; Creatinine; Doripenem; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method | 2013 |
[In vitro activity of doripenem against strains from pediatric diseases and strains causing purulent meningitis].
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Child; Doripenem; Haemophilus influenzae; Humans; Meningitis, Bacterial; Microbial Sensitivity Tests; Streptococcus pneumoniae; Suppuration | 2012 |
In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Polymyxin B; Rifampin | 2013 |
In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Intensive Care Units; Microbial Sensitivity Tests; Minocycline; Tertiary Healthcare; Tigecycline | 2013 |
The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
Topics: Adolescent; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Carbapenems; Child; Cystic Fibrosis; Disease Progression; Doripenem; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas stutzeri; Rhodospirillaceae; Thienamycins; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Chromatography, Liquid; Cross Infection; Doripenem; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Plasma; Pneumonia, Bacterial; Tandem Mass Spectrometry; Time Factors | 2013 |
In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Doripenem; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Minocycline; Models, Theoretical; Sulbactam; Tigecycline | 2013 |
Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Time Factors | 2013 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia, Ventilator-Associated; Random Allocation; Survival Analysis | 2013 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
Topics: Acinetobacter baumannii; Bacterial Infections; Carbapenems; Doripenem; Electrophoresis, Gel, Pulsed-Field; Europe; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sensitivity and Specificity; Species Specificity; Thienamycins; United States; United States Food and Drug Administration | 2013 |
IMP-43 and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Japan; Meropenem; Phylogeny; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Thienamycins | 2013 |
Structures of the class D Carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam.
Topics: Acinetobacter; Amino Acid Sequence; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Crystallography, X-Ray; Doripenem; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid | 2013 |
Effect of pulmonary surfactant on antimicrobial activity in vitro.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Carbapenems; Colistin; Daptomycin; Doripenem; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Oxazolidinones; Pulmonary Surfactants; Quinolines; Staphylococcus aureus; Swine; Tigecycline | 2013 |
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gene Expression; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Multivariate Analysis; Mutation; Porins; Promoter Regions, Genetic | 2013 |
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.
Topics: Antitubercular Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cell Wall; Clavulanic Acid; Doripenem; Enzyme Assays; Ertapenem; Escherichia coli; Gene Expression; Imipenem; Kinetics; Meropenem; Mycobacterium tuberculosis; Peptidoglycan; Peptidyl Transferases; Recombinant Proteins; Thienamycins | 2013 |
Successful treatment of post-neurosurgical multidrug-resistant Pseudomonas aeruginosa meningo-encephalitis with combination therapy of colistin, rifampicin and doripenem.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Meningoencephalitis; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Surgical Wound Infection; Treatment Outcome | 2014 |
Pseudohemoptysis due to Serratia marcescens.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cross Infection; Diagnosis, Differential; Doripenem; Hemoptysis; Humans; Male; Serratia Infections; Serratia marcescens; Sputum; Treatment Outcome | 2014 |
In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Sulbactam | 2014 |
In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Humans; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
[Case report; a case of lung and skin nocardiosis in a non-immunocompromised patient].
Topics: Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Diagnosis, Differential; Doripenem; Drainage; Humans; Male; Nocardia asteroides; Nocardia Infections; Opportunistic Infections; Radiography, Thoracic; Skin Diseases, Bacterial; Sputum; Suppuration; Tomography, X-Ray Computed | 2013 |
Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
Topics: Algorithms; Anti-Bacterial Agents; Aspartic Acid; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Therapy, Combination; Genotype; Gentamicins; Glycine; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutagenesis, Insertional; Porins | 2014 |
Biochemical analysis of metallo-β-lactamase NDM-3 from a multidrug-resistant Escherichia coli strain isolated in Japan.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Japan; Microbial Sensitivity Tests; Plasmids | 2014 |
Importance of early appropriate intervention including antibiotics and wound care for device-related infection in patients with left ventricular assist device.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Carbapenems; Doripenem; Female; Heart-Assist Devices; Humans; Male; Retrospective Studies; Teicoplanin; Wounds and Injuries | 2014 |
[Studies on the distribution of doripenem in pancreatic tissues, especially on the importance of the ratio in pancreatic tissue concentration of doripenem/serum concentration of doripenem].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Doripenem; Humans; Pancrelipase | 2014 |
Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Topics: Anti-Bacterial Agents; Biofilms; Carbapenems; Colistin; Colony Count, Microbial; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2014 |
Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Plasma; Young Adult | 2014 |
Molecular epidemiology of NDM-1-producing Enterobacteriaceae and Acinetobacter baumannii isolates from Pakistan.
Topics: Acinetobacter baumannii; Amdinocillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; DNA, Bacterial; Doripenem; Enterobacteriaceae; Fosfomycin; Humans; Meropenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Pakistan; Thienamycins | 2014 |
Crystal chemistry of the antibiotic doripenem.
Topics: Anti-Bacterial Agents; Calorimetry, Differential Scanning; Carbapenems; Chemistry, Pharmaceutical; Crystallization; Crystallography, X-Ray; Doripenem; Hydrogen Bonding; Models, Molecular; Molecular Structure; Powder Diffraction; Technology, Pharmaceutical; Temperature; Thermogravimetry; Water | 2014 |
The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Carbapenems; Critical Care; Doripenem; Humans; Microbial Sensitivity Tests; Middle Aged; Multiple Organ Failure; Renal Dialysis; Sepsis | 2014 |
Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Colony Count, Microbial; Doripenem; Microbial Sensitivity Tests; Models, Statistical | 2015 |
[A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Topics: Carbapenems; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2014 |
Kinetic and structural requirements for carbapenemase activity in GES-type β-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Ertapenem; Escherichia coli; Kinetics; Meropenem; Models, Molecular; Thienamycins | 2015 |
Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Computer Simulation; Doripenem; Humans; Japan; Middle Aged; Models, Biological; Models, Statistical; Monte Carlo Method; Renal Insufficiency; Young Adult | 2015 |
Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit.
Topics: Carbapenems; Colistin; Doripenem; Dose-Response Relationship, Drug; Drug Combinations; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Minocycline; Rifampin; Tigecycline; Tobramycin | 2014 |
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Therapy, Combination; Female; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Porins; Retrospective Studies | 2015 |
The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Gene Expression Profiling; Models, Theoretical; Sequence Analysis, RNA; Time Factors | 2015 |
Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Hydrolysis; Microbial Sensitivity Tests; Mutation Rate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; RNA, Messenger | 2015 |
Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Pseudomonas aeruginosa; Time Factors | 2015 |
Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Male; Mice; Mice, Inbred BALB C; Minocycline; Sepsis; Sulbactam; Tigecycline | 2015 |
[Pharmacokinetics study of injected doripenemin healthy volunteers].
Topics: Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Healthy Volunteers; Humans; Infusions, Intravenous; Meropenem; Thienamycins | 2015 |
Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Child; Doripenem; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Streptococcus pneumoniae | 2015 |
Evaluation of a pharmacokineticpharmacodynamic approach using software to optimize the carbapenem antibiotic regimen.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Computer Simulation; Doripenem; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Drug Therapy, Computer-Assisted; Female; Humans; Kidney; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Pneumonia, Bacterial; Prospective Studies; Software; Thienamycins; Treatment Outcome | 2015 |
Profiling of β-lactam selectivity for penicillin-binding proteins in Streptococcus pneumoniae D39.
Topics: Amdinocillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cephalosporins; Doripenem; Electrophoresis, Polyacrylamide Gel; Meropenem; Penicillin-Binding Proteins; Streptococcus pneumoniae; Thienamycins | 2015 |
Antimicrobial resistance surveillance of doripenem in China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; China; Doripenem; Drug Resistance, Bacterial; Enterobacteriaceae; Epidemiological Monitoring; Hospitals; Humans; Microbial Sensitivity Tests; Prevalence; Pseudomonas aeruginosa | 2015 |
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Doripenem; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Rifampin; Thienamycins | 2015 |
IMP-51, a novel IMP-type metallo-β-lactamase with increased doripenem- and meropenem-hydrolyzing activities, in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate.
Topics: beta-Lactamases; Carbapenems; Cefoxitin; Doripenem; Escherichia coli; Meropenem; Microbial Sensitivity Tests; Moxalactam; Pseudomonas aeruginosa; Thienamycins | 2015 |
Role of efflux pumps inhibitor in decreasing antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in North India.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Doripenem; Drug Resistance, Bacterial; Ertapenem; Genotype; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Polymerase Chain Reaction; Tigecycline | 2015 |
In Vitro Efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-Test.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Doripenem; Female; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Malaysia; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Prospective Studies; Pseudomonas aeruginosa; Sepsis; Survival Analysis | 2016 |
Quantitative determination of the β-methyl carbapenem doripenem in powder for injection by a stability-indicating capillary zone electrophoresis method.
Topics: Anti-Bacterial Agents; Carbapenems; Chromatography, High Pressure Liquid; Doripenem; Drug Stability; Electrophoresis, Capillary; Injections; Limit of Detection; Powders; Reference Standards; Reproducibility of Results | 2015 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin | 2015 |
In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Minocycline; Multilocus Sequence Typing; Tigecycline | 2016 |
Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine,
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Doripenem; Feces; Fluoroquinolones; Heterocyclic Compounds, 3-Ring; Humans; Imipenem; Linezolid; Naphthyridines; Oxazines; Oxolinic Acid; Pefloxacin; Piperazines; Pyridones; Retrospective Studies; Rifampin | 2016 |
Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Retrospective Studies; Thienamycins | 2016 |
[Analysis of carbapenems by hydrophilic interaction chromatography and its application].
Topics: beta-Lactams; Carbapenems; Chromatography; Doripenem; Drinking Water; Ertapenem; Humans; Hydrophobic and Hydrophilic Interactions; Meropenem; Thienamycins | 2015 |
Clinical efficacy and safety of high-dose doripenem in Japanese patients with pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Humans; Japan; Male; Pneumonia, Bacterial; Prospective Studies; Sputum; Treatment Outcome | 2016 |
Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Doripenem; Drug Synergism; Microbial Sensitivity Tests; Mutation; Polymyxin B; Pseudomonas aeruginosa | 2016 |
MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cross-Sectional Studies; Doripenem; Drug Resistance, Multiple; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Structural Insights into Recognition of Hydrolyzed Carbapenems and Inhibitors by Subclass B3 Metallo-β-Lactamase SMB-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; beta-Lactamases; Captopril; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Imipenem; Meropenem; Mesna; Protein Structure, Secondary; Protein Structure, Tertiary; Serratia marcescens; Thienamycins | 2016 |
Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Iran; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2016 |
Pyogenic vertebral osteomyelitis caused by Yersinia pseudotuberculosis.
Topics: Aged; Blood Culture; Carbapenems; Clindamycin; Discitis; Doripenem; Drug Therapy, Combination; Fever; Follow-Up Studies; Humans; Infusions, Intravenous; Low Back Pain; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Osteomyelitis; Rare Diseases; Thoracic Vertebrae; Treatment Outcome; Yersinia pseudotuberculosis; Yersinia pseudotuberculosis Infections | 2016 |
Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins; Treatment Outcome | 2016 |
Bacteremia Due to Arthrobacter creatinolyticus in an Elderly Diabetic Man with Acute Cholangitis.
Topics: Aerobiosis; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Arthrobacter; Bacteremia; beta-Lactamase Inhibitors; Carbapenems; Cholangitis; Diabetes Complications; DNA, Bacterial; DNA, Ribosomal; Doripenem; Gram-Positive Bacterial Infections; Humans; Male; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Sulbactam | 2017 |
In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Doripenem; Drug Resistance, Bacterial; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Minocycline; Rifampin; Tigecycline | 2017 |
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Taiwan; Thienamycins | 2016 |
Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gentamicins; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Tigecycline; Vietnam | 2016 |
The structure of a doripenem-bound OXA-51 class D β-lactamase variant with enhanced carbapenemase activity.
Topics: Acinetobacter baumannii; Amino Acid Substitution; beta-Lactamases; Binding Sites; Carbapenems; Crystallography, X-Ray; Doripenem; Molecular Dynamics Simulation; Mutation, Missense | 2016 |
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Critical Illness; Doripenem; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Sepsis; Wounds and Injuries | 2016 |
Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Carbapenems; Cross Infection; Doripenem; Female; Hospital Mortality; Humans; Intraabdominal Infections; Male; Middle Aged; Respiratory Tract Infections; Retrospective Studies; Soft Tissue Infections; Tertiary Care Centers; Treatment Outcome; Urinary Tract Infections | 2016 |
Maculopapular eruption caused by doripenem.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Pneumonia | 2017 |
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Critical Care; Doripenem; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Gene Expression; Genotype; Humans; Imipenem; Klebsiella; Klebsiella Infections; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Thienamycins; United States | 2017 |
Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Mass Index; Body Weight; Carbapenems; Doripenem; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Obesity | 2017 |
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2017 |
Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bayes Theorem; Carbapenems; Doripenem; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Prostatitis; Urinary Tract Infections; Young Adult | 2017 |
Investigation of genotoxic effects of doripenem using cytogenetic and molecular methods.
Topics: Anti-Bacterial Agents; Carbapenems; Cell Nucleus; Cells, Cultured; Chromosome Aberrations; Doripenem; Genomic Instability; Humans; Lymphocytes; Micronucleus Tests; Random Amplified Polymorphic DNA Technique | 2017 |
Multiple substitutions lead to increased loop flexibility and expanded specificity in
Topics: Acinetobacter baumannii; Amino Acid Sequence; Amino Acid Substitution; Bacterial Proteins; beta-Lactamases; Carbapenems; Catalytic Domain; Cefotaxime; Cloning, Molecular; Crystallography, X-Ray; Doripenem; Escherichia coli; Gene Expression; Genetic Vectors; Imipenem; Kinetics; Models, Molecular; Mutation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity | 2018 |
Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Topics: beta-Lactam Resistance; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Reagent Strips; Sensitivity and Specificity | 2018 |
Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Catalytic Domain; Doripenem; Hydrophobic and Hydrophilic Interactions; Imipenem; Meropenem; Microbial Sensitivity Tests; Protein Structure, Secondary | 2019 |
Molecular docking, dynamics and free energy analyses of
Topics: Acinetobacter baumannii; Ampicillin; beta-Lactamases; Carbapenems; Catalytic Domain; Computer Simulation; Doripenem; Ertapenem; Hydrolysis; Meropenem; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation | 2020 |
A method to quantify viable carbapenem resistant gram-negative bacteria in treated and untreated wastewater.
Topics: Anti-Bacterial Agents; Bacterial Load; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Disk Diffusion Antimicrobial Tests; Doripenem; Ertapenem; Imipenem; Meropenem; Wastewater; Water Purification | 2020 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Auranofin promotes antibacterial effect of doripenem against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Auranofin; Bacterial Proteins; beta-Lactamases; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests | 2022 |
Association between Antimicrobial Consumption and the Prevalence of Nosocomial Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae in a Tertiary Hospital in Northern Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cross Infection; Doripenem; Escherichia coli; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Prevalence; Retrospective Studies; Taiwan; Tertiary Care Centers | 2022 |
Carbapenem resistance gene crisis in A. baumannii: a computational analysis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Doripenem; Imipenem; Meropenem; Molecular Docking Simulation | 2022 |
Molecular docking and dynamic approach to screen the drug candidate against the Imipenem-resistant CarO porin in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Porins | 2023 |
Risk evaluation of carbapenem-induced liver injury based on machine learning analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Chemical and Drug Induced Liver Injury, Chronic; Doripenem; Humans; Meropenem | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |